TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02668458

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High Flow nasal canula oxygen therapy
Description: Pre-oxygenation with high-flow nasal canula oxygen therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation
Description: Pre-oxygenation with non-invasive ventilation
Study: NCT00659074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: ODT, single-dose, fasting
Study: NCT05127707

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Words Matter - Visual Campaign & Narrative Vignette (Messenger: Clinician)
Description: Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings combined with a narrative vignette told from the perspective of a clinician working with patients with opioid use disorder
Study: NCT00659074

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zofran
Description: ODT, single-dose, fasting
Study: NCT03955614

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pedal-controlled GoSurgeryTM
Description: Members of the surgical team are given operative instruction workflows to use in preparation of a specific operation and to consult during the operation if needed. The workflows are controlled by the surgical staff using pedals.~The operating theatre environment is recorded to observe how teamwork may be affected by the intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pedal-controlled GoSurgeryTM
Description: Members of the surgical team are given operative instruction workflows to use in preparation of a specific operation and to consult during the operation if needed. The workflows are controlled by the surgical staff using pedals.~The operating theatre environment is recorded to observe how teamwork may be affected by the intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pedal-controlled GoSurgeryTM
Description: Members of the surgical team are given operative instruction workflows to use in preparation of a specific operation and to consult during the operation if needed. The workflows are controlled by the surgical staff using pedals.~The operating theatre environment is recorded to observe how teamwork may be affected by the intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ML-controlled GoSurgeryTM
Description: Members of the surgical team are given operative instruction workflows to use in preparation of a specific operation and to consult during the operation if needed. The workflows are projected onto screen based on the machine learning algorithm's determination of current operative step.~The operating theatre environment is recorded to observe how teamwork may be affected by the intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ML-controlled GoSurgeryTM
Description: Members of the surgical team are given operative instruction workflows to use in preparation of a specific operation and to consult during the operation if needed. The workflows are projected onto screen based on the machine learning algorithm's determination of current operative step.~The operating theatre environment is recorded to observe how teamwork may be affected by the intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ML-controlled GoSurgeryTM
Description: Members of the surgical team are given operative instruction workflows to use in preparation of a specific operation and to consult during the operation if needed. The workflows are projected onto screen based on the machine learning algorithm's determination of current operative step.~The operating theatre environment is recorded to observe how teamwork may be affected by the intervention.
Study: NCT05127707

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Words Matter - Visual Campaign & Narrative Vignette (Messenger: Health System Administrator)
Description: Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings combined with a narrative vignette told from the perspective of a health system administrator/leader
Study: NCT03955614

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NoGo
Description: The operating theatre environment is recorded to observe baseline teamwork.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NoGo
Description: The operating theatre environment is recorded to observe baseline teamwork.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NoGo
Description: The operating theatre environment is recorded to observe baseline teamwork.
Study: NCT01337336

Intervention type: DRUG
Intervention: fluticasone propionate/salmeterol xinafoate
Description: combination fluticasone priopionate and salmeterol xinafoate 250/50mcg

Intervention type: DRUG
Intervention: Anticholinergics
Description: tiotropium; ipratropium alone; or ipratropium + albuterol
Study: NCT04619615

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Asynchronous self-directed digital training
Description: Resident participants will be able to complete the digital training at their own pace.
Study: NCT05127707

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication Treatment for Opioid Use Disorder Works - Visual Campaign
Description: Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication Treatment for Opioid Use Disorder Works - Visual Campaign & Narrative Vignette (Messenger: Person with Opioid Use Disorder)
Description: Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives combined with a narrative vignette told from the perspective of a person with opioid use disorder

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication Treatment for Opioid Use Disorder Works - Visual Campaign & Narrative Vignette (Messenger: Clinician)
Description: Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives combined with a narrative vignette told from the perspective of a clinician who treats people with opioid use disorder
Study: NCT04619615

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Synchronous large group online workshop
Description: Resident participants will complete the digital training platform in real time over the course of a one day, live workshop (4.5 hours of online instruction).
Study: NCT03530943

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Animal Assisted Activities
Description: Students interact with canines in small group settings under the supervision of their handlers during structured and semi-structured activities designed to strengthen physiological, emotion and behavioral regulation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Animal Assisted Activities
Description: Students interact with canines in small group settings under the supervision of their handlers during structured and semi-structured activities designed to strengthen physiological, emotion and behavioral regulation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Academic Stress Management tools
Description: Evidence-based workshops focus on evidence-based content and activities designed to enhance academic stress management knowledge and skills, motivation and learning, adaptive sleep, and study and test-taking behavior through strengthening physiological, emotion and behavioral regulation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Academic Stress Management tools
Description: Evidence-based workshops focus on evidence-based content and activities designed to enhance academic stress management knowledge and skills, motivation and learning, adaptive sleep, and study and test-taking behavior through strengthening physiological, emotion and behavioral regulation
Study: NCT05127707

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication Treatment for Opioid Use Disorder Works - Visual Campaign & Narrative Vignette (Messenger: Health System Administrator)
Description: Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives combined with a narrative vignette told from the perspective of a health system administrator/leader
Study: NCT02246855

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gammaplex® (Human Normal Immunoglobulin)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gammaplex® (Human Normal Immunoglobulin)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gammaplex® (Human Normal Immunoglobulin)
Study: NCT05206721

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Open tracheal suction system flushing with chlorhexidine
Description: After suctioning the patient's secretions, the responsible nurse inserted the SC into the CHX filled container and flushed the entire suction system with CHX.
Study: NCT01505959

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP treatment
Description: Usual CPAP treatment

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP treatment
Description: CPAP treatment with telemedicine system
Study: NCT00811603

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin (Timing of Antibiotic Prophylaxis)
Description: Patients scheduled for a cesarean delivery will be randomly assigned to receive Cefazolin (antibiotic prophylaxis) either prior to skin incision or after the clamping of the umbilical cord

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin (Timing of Antibiotic Prophylaxis)
Description: Patients scheduled for a cesarean delivery will be randomly assigned to receive Cefazolin (antibiotic prophylaxis) either prior to skin incision or after the clamping of the umbilical cord
Study: NCT04038489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin (60 mg/m2) Given by IV with cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide (600 mg/m2) Given by IV with doxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m2 or 175 mg/m2 based on provider preference. Given by IV after completion of doxorubicin/cyclophosphamide therapy
Study: NCT02900820

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discontinuing antibiotic therapy
Description: Patients assigned to this group will be asked to discontinue antibiotic therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuing antibiotic therapy
Description: Patients assigned to this group will be asked to complete antibiotic therapy.
Study: NCT01752205

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 45mg/m2/w,total 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 45mg/m2/w,total 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150mg/d,days 1-42,total 6 weeks

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Study: NCT01226225

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic interval training
Description: Patients will enter a training program during which aerobic interval training is implemented. Three sessions per week, each lasting for 60 minutes. Total duration of the program: 3 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate endurance training
Description: Patients will enter a training program during which moderate endurance training is implemented. Three sessions per week, each lasting for 60 minutes. Total duration of the program: 3 months.
Study: NCT00764361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxycycline
Description: 1.0% doxycycline gel applied topically to the wound once daily for 20 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo gel
Description: placebo gel applied topically to the wound once daily for 20 weeks
Study: NCT00547651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amrubicin
Description: Amrubicin for injection is supplied as 50-mg vials. Patients will receive 40 mg/m2 amrubicin as a 5-minute infusion once daily for 3 consecutive days starting on Day 1 of a 21-day course

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: Topotecan for injection is supplied as 4-mg vials. Patients will receive 1.5 mg/m2 as a 30-minute infusion once daily for 5 consecutive days starting on Day 1 of a 21-day course
Study: NCT03471273

Intervention type: PROCEDURE
Group type: OTHER
Intervention: endoscopic management, surgery and follow up
Description: endoscopic management, surgery and follow up

Intervention type: PROCEDURE
Group type: OTHER
Intervention: endoscopic management, surgery and follow up
Description: endoscopic management, surgery and follow up

Intervention type: PROCEDURE
Group type: OTHER
Intervention: endoscopic management, surgery and follow up
Description: endoscopic management, surgery and follow up
Study: NCT02079038

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Totalis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Comparator Surgical Procedure
Study: NCT03572452

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: McKenzie Method
Description: Treatment according to the Mechanical Diagnosis and Therapy Approach

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Advice to saty active
Description: Physiotherapy councelling advicing to stay normally active
Study: NCT00970918

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Measurement of the Carotid Intima Media thickness
Description: one time, radiological procedure on both sides of the neck

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample testing for hs-CRP
Description: one time, blood sample taking
Study: NCT01558947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peri-operative chemotherapy of ECX
Description: Preoperative chemotherapy of ECX for 3 cycles(Epirubicin 50mg/m2 on day 1; capecitabine 1000mg/m2, 2 times / day, 1 to 14 days; cisplatin 60mg/m2 on day 1, need hydration, 21 day/cycle), operation after 2\~4 weeks, and postoperative chemotherapy of ECX for 3 cycles 4\~6 weeks after surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peri-operative chemotherapy of XP
Description: Preoperative chemotherapy of XP for 3 cycles(capecitabine 1000mg/m2, 2 times / day, 1 to 14 days; cisplatin 60mg/m2 on day 1, need hydration, 21 day/cycle), operation after 2\~4 weeks, and postoperative chemotherapy of XP for 3 cycles 4\~6 weeks after surgery.
Study: NCT00006107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT02083692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study: NCT03527472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Memantine is an FDA-approved drug for the treatment of Alzheimer's disease.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will match the study drug in appearance, dose, and frequency. It will not contain any active drug (memantine).
Study: NCT02152709

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3 dose of 10µg/0.5ml hepatitis B vaccine
Description: 3 dose of 10µg/0.5ml hepatitis B vaccine made by recombinant deoxyribonudeic acid techniques in saccharomyces cereviside were administered intramuscular injection at 0, 1, 6 momth interval.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 3 dose of 5µg/0.5ml hepatitis B vaccine
Description: 3 dose of 5µg/0.5ml hepatitis B vaccine made by recombinant deoxyribonudeic acid techniques in saccharomyces cereviside were administered intramuscular injection at 0, 1, 6 momth interval.
Study: NCT00808093

Intervention type: DRUG
Group type: OTHER
Intervention: GSK256073
Description: GSK256073 100 mg study drug
Study: NCT01410513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR245409
Description: Pharmaceutical form:capsule Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR245409
Description: Pharmaceutical form:capsule Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR245409
Description: Pharmaceutical form:capsule Route of administration: oral
Study: NCT00985465

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK1024850A
Description: Intramuscular injection, 1 or 2 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK1024850A
Description: Intramuscular injection, 1 or 2 doses
Study: NCT02466763

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cochlear implant surgery
Description: Surgical placement of a cochlear implant device.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cochlear implant surgery
Description: Surgical placement of a cochlear implant device.
Study: NCT01897363

Intervention type: OTHER
Intervention: Infants with Prader-Willi Syndrome
Description: Participants will be admitted to the outpatient clinical research center for IV placement, blood draws from the IV, poking the participants finger to obtain small amounts of blood and monitored 6 hour fast.
Study: NCT01618669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson
Description: Administered as an intravenous (IV) bolus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regadenoson
Description: Administered as an intravenous (IV) bolus

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI)
Study: NCT01923207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DX-2930

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo, subcutaneous administration
Study: NCT04117204

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fruits and Vegetables
Description: Fruits and Vegetable delivery, once a week for 12 weeks.
Study: NCT02116881

Intervention type: PROCEDURE
Intervention: Colorectal Surgery
Description: Application of postoperative questionnaires will be completed by patients. The intervention is the standard of care.

Intervention type: PROCEDURE
Intervention: Colorectal Surgery
Description: Application of postoperative questionnaires will be completed by patients. The intervention is the standard of care.
Study: NCT04438694

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma
Description: Convalescent Plasma

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of Care drugs administered as per Cairo University ICU protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care drugs administered as per Cairo University ICU protocol
Study: NCT00700596

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salvinorin A
Description: Low dose: Active SA 250μg Medium Dose: Active SA 500μg High Dose: Active SA 750μg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control or Placebo SA (30 % ethanolic solution)
Study: NCT01702558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine will be administered at de-escalating doses (starting from 750 mg/m\^2) to determine the MTD.
Study: NCT01525407

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo myeloablative allogeneic PBSC transplant
Study: NCT01702558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine (T-DM1)
Description: Trastuzumab emtansine will be administered at a dose of 3.6 mg/kg via IV infusion every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine (T-DM1)
Description: Trastuzumab emtansine will be administered at a dose of 3.6 mg/kg via IV infusion every 3 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab emtansine (T-DM1)
Description: Trastuzumab emtansine will be administered at a dose of 3.6 mg/kg via IV infusion every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine (T-DM1)
Description: Trastuzumab emtansine will be administered at a dose of 2.4 mg/kg via IV infusion every week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine will be administered at the MTD determined in Cohort 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine will be administered at the MTD determined in Cohort 1.
Study: NCT01525407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin Calcium
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo myeloablative allogeneic PBSC transplant
Study: NCT03815227

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Outpatient birth
Description: Maternity out the same date or the next day of the birth and home-based follow up with a liberal midwife
Study: NCT00929552

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary oils (fish, vegetable oil)
Description: 6g pr day.